Xvivo Perfusion AB
Research Xvivo Perfusion AB (XVIVO) on Bullrun: valuation model: 27.5% overvalued, market cap SEK 7.98B, P/E 107.7. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerXVIVO
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryMedical Devices
- CurrencySEK
- Valuation signal27.5% overvalued
- Market capSEK 7.98B
- P/E107.7
- Financial periodQ1 2026
- RevenueSEK 240.96M
- Net incomeSEK 36.30M
- Free cash flowSEK 65.34M
- Gross margin71.0%
Valuation Snapshot
Bullrun's latest valuation model marks Xvivo Perfusion AB as 27.5% overvalued; latest market cap is SEK 7.98B; P/E is 107.7.
About Xvivo Perfusion AB
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours;
Frequently asked questions
Is Xvivo Perfusion AB overvalued or undervalued?
Bullrun's valuation model currently marks Xvivo Perfusion AB as 27.5% overvalued.
What is Xvivo Perfusion AB's market cap?
Xvivo Perfusion AB's market capitalization is SEK 7.98B.
What is Xvivo Perfusion AB's P/E ratio?
Xvivo Perfusion AB's price-to-earnings (P/E) ratio is 107.7.
What does Xvivo Perfusion AB do?
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments.